Drug reference
phytonadione
Vitamin K · Vitamin supplement
Vitamin KVitamin supplement
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Phytonadione is Vitamin K1, an essential cofactor in the γ-carboxylation of multiple glutamate residues of clotting factors (II, VII, IX, X) and anticoagulant proteins (C, S, Z). It promotes the biosynthesis of these factors, which are necessary for blood coagulation.
Indications
correction of bleeding tendency or hemorrhage associated with vitamin K deficiencyreversal of warfarin effectshypoprothrombinemia of the newbornbiliary obstructionmalnutritionProphylaxis and treatment of bleeding due to vitamin K deficiencyDietary vitamin K deficiencyProlonged antimicrobial therapyObstructive jaundiceMalabsorption syndromes (sprue, regional ileitis, steatorrhoea)Newborn hypoprothrombinemia (prevention of haemorrhagic disease of the newborn)Overdose of oral anticoagulantsProlonged high dose salicylate therapy (prophylaxis of hypoprothrombinemia)
Dosing
- Adult
- For prolonged intravenous alimentation, 1 mg per week (equivalent of about 150 μg/day) to prevent hypoprothrombinemia. For biliary obstruction or fistula, 10 mg daily. For hepatocellular disease or long-standing biliary obstruction, 10 mg daily parenterally.
- Pediatric
- Routine administration of 1 mg intramuscularly at birth for hypoprothrombinemia of the newborn. Dose may need to be increased or repeated if mother received warfarin or anticonvulsant therapy, or if infant develops a bleeding diathesis.
- Renal adjustment
- In severe hepatitis or cirrhosis (associated with inadequate utilization), large doses of vitamin K or its analogues can paradoxically contribute to a further reduction in prothrombin levels.
Pharmacokinetics
Onset
rapidly corrects hypoprothrombinemia in the neonate, controlling bleeding within about 6 hours
Protein binding
Only temporarily concentrated in liver, no significant body stores.
Metabolism
incorporated into chylomicrons and associated with triglycerides and lipoproteins after absorption
Excretion
concentrated in the liver, but concentration declines rapidly
Contraindications
- rapid intravenous infusion (can cause severe reactions resembling anaphylaxis)
- subcutaneous route in patients with a coagulopathy (due to risk of bleeding)
Side effects
Serious
- hemolytic anemia (with synthetic forms in neonates)
- kernicterus (with synthetic forms in neonates)
- Severe anaphylactoid reactions (on i.v. injection of emulsified formulation)
- Haemolysis (with menadione and water-soluble derivatives, especially in G-6-PD deficient patients and neonates)
- Kernicterus (with menadione/its salts in newborns)
Related guidelines
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Iron deficiency anaemia in pregnancy
ICMR · Obstetrics & Gynaecology · 2022
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Chronic obstructive pulmonary disease
GOLD · Pulmonology · 2025
Iron deficiency anaemia in adults
ICMR · Hematology · 2023
Ask House about phytonadione
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team